Eric J. Topol

TL;DR: In the large-scale Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial that involved high-risk patients undergoing coronary intervention procedures, a monoclonal antibody Fab fragment directed against this receptor, administered as a bolus and through infusion, significantly reduced the 30-day incidence of major ischemic events relative to placebo.

TL;DR: The results suggest automated health tracking could significantly improve long-term health engagement, and individuals who entered activities automatically through supported devices or apps participated roughly four times longer than their manual activity-entering counterparts.

TL;DR: The positive data for restenosis reduction from the randomized trials of the Palmaz-Schatz stent in the BENESTENT and STRESS trials set a new precedent by having such data available before a new medical device approval, and led to a rapid and major revamping of clinical practice.

TL;DR: Mortality within the first 24 h of thrombolytic therapy administration can be defined by inadequate myocardial reperfusions in patients with cardiac failure, possibly associated reperfusion injury leading to cardiac rupture, and an increased risk of intracranial hemorrhage.

TL;DR: New findings show that the variability in clopidogrel efficacy is affected by the enzyme paraoxonase-1 (PON1), which is required for clopIDogrel bioactivation.